Latest News from ASCO in Action

Latest News from ASCO in Action

October 31, 2014

This afternoon the Centers for Medicare & Medicaid Services (CMS) released its final rule on the 2015 Medicare Physician Fee Schedule. The rule, which became available today, October 31, 2014, is scheduled to be published in the Federal Register on November 13, 2014.

October 22, 2014

The U.S. Food and Drug Administration’s recently released final Guidance for Industry on Pathological Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer incorporates two changes that ASCO had proposed in comments submitted to the agency on a draft guidance issued in 2012.

October 20, 2014

In the next few weeks, the American Society of Clinical Oncology (ASCO) in collaboration with multiple specialty societies will randomly distribute an American Medical Association (AMA) Relative Value Scale Update Committee (RUC) survey of the therapeutic injection CPT ® codes 96372, 96374, and 96375 the chemotherapy injection CPT ® codes 96401, 96409, and 96411. These services are utilized widely by ASCO members and we need your assistance to ensure the relative value units (RVUs) are accurately and fairly presented to the Centers for Medicare and Medicaid Services (CMS).

ASCO's ACT Network

ASCO's ACT Network

ALERT CONGRESS TODAY! Use ASCO's ACT Network to contact your elected officials on important policy issues impacting cancer care. 

ASCO Issue Backgrounders

ASCO Issue Backgrounders

ASCO offers issue backgrounders to help provide an overview of the major policy issues that impact patients with cancer and the physicians who care for them. The issue backgrounders cover topics such as reimbursement, health equity, cancer research funding, and more.

Click here to read the backgrounds and help develop your understanding of cancer policy issues.

NIH Funding Educational Series

NIH Funding Educational Series

ASCO explores the decade-long decline in federal funding for cancer research – and why this decline must be reversed. Read more here.